Anna Josephine Gebhardt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna Josephine Gebhardt has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Friedrich Koch-Nolte
Institute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2 shared publications - Julia Hambach
Institute of Immunology University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany
2 shared publications - Alessa Zoe Schaffrath
Research Department Cell and Gene Therapy, Department of Stem Cell Transplantation University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany
1 shared publication Anya Duttmann
Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1 shared publication- Boris Fehse
Research Department Cell and Gene Therapy, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
1 shared publication - Constantin Möller
Research Department Cell and Gene Therapy, Department of Stem Cell Transplantation University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany
1 shared publication
Latest Publications
- Open Access
Novel Bispecific Engagers Targeting the CεmX Domain of mIgE ‐Expressing Cells
Background: IgE‐associated allergic diseases, affecting approximately 30% of the global population, are a major health burden. Standard treatments, including pharmacotherapy and allergen immunotherapy (AIT), have limitations such as adverse effects, insufficient symptom relief and long treatment durations. Methods: In this study, we developed and evaluated a bispecific T‐cell engager (TCE) and a half‐life extended (HLE) bispecific natural killer (NK) cell engager (NKCE) targeting IgE‐producing cells, to offer novel, potentially curative therapeutic options. The TCE and HLE‐NKCE constructs were designed to target the CεmX domain of membrane‐bound IgE (mIgE) and engage T cells and NK cells, respectively. Their efficacy was assessed through in vitro luciferase‐based cytotoxicity assays using Ramos and U266 B‐cell lines expressing mIgE as target cells, and primary human immune effector cells and the NK‐cell line NK‐92 as effector cells. Additional characterisation of the constructs was performed using flow cytometry. Results: Both TCE and HLE‐NKCE specifically mediated killing of CεmX‐expressing cells in a dose‐ and effector‐to‐target (E:T) ratio‐dependent manner. The TCE demonstrated robust activity even at low antigen densities and concentrations as low as 1 ng/mL (18 pM). The HLE‐NKCE effectively mediated killing in the presence of human serum albumin, suggesting functionality in physiological conditions. T‐ and NK‐cell activation was observed only in the presence of target cells and TCE. Conclusion: Our novel anti‐CεmX TCE and HLE‐NKCE effectively target and eliminate mIgE‐expressing cells in vitro. Although further investigation is needed, our bispecific engagers are promising off‐the‐shelf therapeutics for the treatment of IgE‐associated allergic diseases.
Open AccessNovel Bispecific Engagers Targeting the CεmX Domain of mIgE ‐Expressing Cells
Background: IgE‐associated allergic diseases, affecting approximately 30% of the global population, are a major health burden. Standard treatments, including pharmacotherapy and allergen immunotherapy (AIT), have limitations such as adverse effects, insufficient symptom relief and long treatment durations. Methods: In this study, we developed and evaluated a bispecific T‐cell engager (TCE) and a half‐life extended (HLE) bispecific natural killer (NK) cell engager (NKCE) targeting IgE‐producing cells, to offer novel, potentially curative therapeutic options. The TCE and HLE‐NKCE constructs were designed to target the CεmX domain of membrane‐bound IgE (mIgE) and engage T cells and NK cells, respectively. Their efficacy was assessed through in vitro luciferase‐based cytotoxicity assays using Ramos and U266 B‐cell lines expressing mIgE as target cells, and primary human immune effector cells and the NK‐cell line NK‐92 as effector cells. Additional characterisation of the constructs was performed using flow cytometry. Results: Both TCE and HLE‐NKCE specifically mediated killing of CεmX‐expressing cells in a dose‐ and effector‐to‐target (E:T) ratio‐dependent manner. The TCE demonstrated robust activity even at low antigen densities and concentrations as low as 1 ng/mL (18 pM). The HLE‐NKCE effectively mediated killing in the presence of human serum albumin, suggesting functionality in physiological conditions. T‐ and NK‐cell activation was observed only in the presence of target cells and TCE. Conclusion: Our novel anti‐CεmX TCE and HLE‐NKCE effectively target and eliminate mIgE‐expressing cells in vitro. Although further investigation is needed, our bispecific engagers are promising off‐the‐shelf therapeutics for the treatment of IgE‐associated allergic diseases.
- Open Access
- 18 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 40376
CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells
Bispecific antibody recruiters (BARs) are an innovative class of immunotherapeutics that redirect endogenous antibodies to tumor cells. BARs comprise a tumor-binding and an antibody-binding module, enabling endogenous antibodies to opsonize tumor cells and induce F C -dependent effector functions such as complement-dependent cytotoxicity (CDC). CD38 is a validated target for myeloma therapy, as evidenced by the success of CD38-specific monoclonal antibodies daratumumab and isatuximab. Nanobodies are single variable immunoglobulin domains derived from camelid heavy chain antibodies. Here, we report the generation of nanobody-based BARs recognizing CD38 and assess their cytotoxicity against CD38-expressing myeloma cells in vitro and ex vivo. We constructed three CD38-specific BARs recognizing distinct, non-overlapping CD38 epitopes (E1-BAR, E2-BAR, and E3-BAR) by genetically fusing CD38-specific nanobodies to a human immunoglobulin κ light chain-specific nanobody. All BARs exhibited simultaneous binding to CD38 and IgGκ. Nonlinear regression revealed EC 50 values of 0.73 nM (E1-BAR), 0.21 nM (E2-BAR), and 0.97 nM (E3-BAR). In patient-derived myeloma cells, E1-BAR reduced viability to 29 ± 18%, while E2-BAR and E3-BAR achieved 62 ± 49% and 57 ± 41%, respectively. In vivo, BAR half-life was markedly increased by IgGκ binding. Our results demonstrate the feasibility of CD38-specific nanobody-based BARs as therapeutics for multiple myeloma.
- 18 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 40376
Open AccessCD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells
Bispecific antibody recruiters (BARs) are an innovative class of immunotherapeutics that redirect endogenous antibodies to tumor cells. BARs comprise a tumor-binding and an antibody-binding module, enabling endogenous antibodies to opsonize tumor cells and induce F C -dependent effector functions such as complement-dependent cytotoxicity (CDC). CD38 is a validated target for myeloma therapy, as evidenced by the success of CD38-specific monoclonal antibodies daratumumab and isatuximab. Nanobodies are single variable immunoglobulin domains derived from camelid heavy chain antibodies. Here, we report the generation of nanobody-based BARs recognizing CD38 and assess their cytotoxicity against CD38-expressing myeloma cells in vitro and ex vivo. We constructed three CD38-specific BARs recognizing distinct, non-overlapping CD38 epitopes (E1-BAR, E2-BAR, and E3-BAR) by genetically fusing CD38-specific nanobodies to a human immunoglobulin κ light chain-specific nanobody. All BARs exhibited simultaneous binding to CD38 and IgGκ. Nonlinear regression revealed EC 50 values of 0.73 nM (E1-BAR), 0.21 nM (E2-BAR), and 0.97 nM (E3-BAR). In patient-derived myeloma cells, E1-BAR reduced viability to 29 ± 18%, while E2-BAR and E3-BAR achieved 62 ± 49% and 57 ± 41%, respectively. In vivo, BAR half-life was markedly increased by IgGκ binding. Our results demonstrate the feasibility of CD38-specific nanobody-based BARs as therapeutics for multiple myeloma.